Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of Botulinum Toxin (BTX) for the Treatment of Peripheral Painful Traumatic Trigeminal Neuropathy (PPTTN)

Next Previous
Trial Profile

Use of Botulinum Toxin (BTX) for the Treatment of Peripheral Painful Traumatic Trigeminal Neuropathy (PPTTN)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Trigeminal neuralgia
  • Focus Therapeutic Use
  • Acronyms TRIGTOX

    • Most Recent Events

    • 25 Jun 2018 Planned End Date changed from 1 Jan 2023 to 1 May 2023.
    • 25 Jun 2018 Planned primary completion date changed from 1 Jun 2022 to 1 Oct 2022.
    • 25 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top